Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10577551
Filing Date		2006-04-28
First Named Inventor SEO		
Art Unit		1624
Examiner Name		
Attorney Docket Number		1751-404

					U.S.I	PATENTS			Remove]	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Date	Name of Pate of cited Docu	entee or Applicant iment	Releva		Lines where ges or Relev	
	1	4699979		1987-10	I-13	Hoshi et al.					
If you wis	h to a	ı dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add]	_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	d Publication de ¹ Date		Name of Patentee of Applicant		Releva	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1										
If you wis	h to a	dd additional U.S. Publ				n information p		d button	Add		_
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	,	Kind Code ⁴	Publication	Name of Patente Applicant of cited Document	or '	vhere Re	or Relevant	
	1	02068428	wo		A1	2002-09-06	Hanmi Pharm. Co.,	Ltd			
	2	02083692	wo		A1	2002-10-24	Hanmi Pharm. Co.,	Ltd			С
	3	03011871	wo		A2	2003-02-13	Biochemie Gesellse M.B.H.	chaft			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10577551
Filing Date		2006-04-28
First Named Inventor	SEO	
Art Unit		1624
Examiner Name		
Attorney Docket Number		1751-404

If you wish to	add add	ditional Foreign Patent Document citation information please click the Ad	d button	Add					
		NON-PATENT LITERATURE DOCUMENTS		Remove					
Examiner Cite Initials* No	e (boo	te name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item , magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), ther, city and/or country where published.							
1		[O et al., "Synthesis and structure-activity relationships of a new oral cephalospot pounds," J. Antibiotics, vol. 40, no. 7, 1997, pp. 991-1005	in, BMY-	28100 and r	elated				
2		RCOM et. al., "Synthesis of 3-alkenylcephalosporins using an epoxide mediated v-Bas, vol. 113, 1994, pp. 305-306	wittig read	ction,* Recl.	Trav. Chim				
3		itNI et al., "An improved procedure for the preparation of a 3-(alkenyl) cephem de na, vol. 127, 1997, pp. 195-196	rivative,"	Gazzetta Ci	nimica				
If you wish to	add add	ditional non-patent literature document citation information please click th	e Add b	utton Ad	d				
		EXAMINER SIGNATURE							
Examiner Sign	nature	Date Consid	lered						
		reference considered, whether or not citation is in conformance with MP rmance and not considered. Include copy of this form with next commun							

F

E

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 2 Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10577551
Filing Date		2006-04-28
First Named Inventor	SEO	
Art Unit		1624
Examiner Name		
Attorney Docket Number		1751-404

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make t	the appropriate selection(s):
---------------	----------	--------------------	-------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/John A. Evans/	Date (YYYY-MM-DD)	2007-08-15
Name/Print	John A Evans	Registration Number	44100

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.